MAXHEALTH.NS · NSI · Healthcare
Max Healthcare Institute Limited
Also onConsensus Drift
Implied value per share
INR 306.03
Market price
INR 1049.30
Implied upside
-70.8%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Current EV/EBITDA of 45.2x sits outside a defensible 3-20x band, so the exit multiple is capped at 20.0x. A multiple that far out usually means EBITDA is the wrong denominator for this business.
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (INR). Outflows negative.
| Line | FY27 | FY28 | FY29 | FY30 | FY31 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | INR 100.7bn | INR 123.2bn | INR 150.7bn | INR 184.4bn | INR 225.7bn | +22.4% |
| EBIT | INR 23.4bn | INR 28.7bn | INR 35.1bn | INR 42.9bn | INR 52.5bn | +22.4% |
| NOPAT | INR 18.2bn | INR 22.2bn | INR 27.2bn | INR 33.3bn | INR 40.7bn | +22.4% |
| Add depreciation & amortisation | INR 5.1bn | INR 6.3bn | INR 7.7bn | INR 9.4bn | INR 11.5bn | +22.4% |
| Less capital expenditure | INR -13.6bn | INR -16.6bn | INR -20.3bn | INR -24.9bn | INR -30.5bn | +22.4% |
| Less increase in working capital | INR -3.6bn | INR -4.4bn | INR -5.3bn | INR -6.5bn | INR -8.0bn | +22.4% |
| Free cashflow to firm | INR 6.1bn | INR 7.5bn | INR 9.2bn | INR 11.2bn | INR 13.7bn | +22.4% |
| Discount factor | 0.9539 | 0.8681 | 0.7900 | 0.7189 | 0.6542 | - |
| Present value | INR 5.8bn | INR 6.5bn | INR 7.3bn | INR 8.1bn | INR 9.0bn | +11.4% |
| Present Value Of The Forecast | INR 36.7bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 6.80% | INR assumption - no free live source available for this market (assumption) |
| Equity risk premium | 8.00% | Market assumption |
| Beta | 0.406 | Reported 0.113, pulled toward 1.0 (Blume) |
| Cost of equity | 10.05% | Risk-free + beta x equity risk premium |
| Cost of debt | 6.80% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | INR 1021.3bn | 96.7% of capital |
| Total debt | INR 34.8bn | 3.3% of capital, book value as a proxy |
| Tax rate | 22.5% | Effective, capped at statutory |
| WACC | 9.89% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
89% of EV
- Forecast FCFF, final year
- INR 13.7bn
- Capex at depreciation, working capital in reinvestment
- INR 42.2bn
- Less reinvestment at g/ROIC (24.2% of NOPAT)
- INR -10.2bn
- Capitalised
- INR 32.0bn
- ROIC (reported)
- 10.4%
- Terminal value, undiscounted
- INR 444.1bn
- Terminal value, discounted
- INR 290.5bn
- Enterprise value
- INR 327.2bn
- Less net debt
- INR 28.1bn
- Equity value
- INR 299.1bn
Exit at 20.0x EBITDA
96% of EV
- Terminal value, undiscounted
- INR 1281.1bn
- Terminal value, discounted
- INR 838.1bn
- Enterprise value
- INR 874.8bn
- Less net debt
- INR 28.1bn
- Equity value
- INR 846.7bn
Spread between methods: 96%.
Sensitivity
Value per share (INR) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 7.89% | 427.56 | 439.51 | 453.41 | 469.84 | 489.69 |
| 8.89% | 355.50 | 361.37 | 367.94 | 375.38 | 383.95 |
| 9.89% | 301.06 | 303.47 | 306.03 | 308.76 | 311.70 |
| 10.89% | 260.68 | 261.92 | 263.17 | 264.42 | 265.66 |
| 11.89% | 229.37 | 230.47 | 231.56 | 232.66 | 233.75 |
Outlined: this model. Green text: above today's price of 1049.30. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 22.4% | 57.2% | +34.8pp |
| EBIT margin | 23.3% | 66.8% | +43.5pp |
| Discount rate | 9.9% | 5.1% | -4.8pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.